Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 19
2013 18
2014 13
2015 8
2016 4
2017 3
2018 3
2019 2
2020 4
2021 9
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey.
Bakırtaş M, Dal MS, Yiğenoğlu TN, Giden AO, Serin I, Başcı S, Kalpakci Y, Korkmaz S, Ekinci O, Albayrak M, Basturk A, Ozatli D, Dogu MH, Hacıbekiroglu T, Çakar MK, Ulas T, Miskioglu M, Gulturk E, Eser B, Altuntas F. Bakırtaş M, et al. Among authors: ulas t. J Chemother. 2023 Oct;35(6):563-569. doi: 10.1080/1120009X.2023.2208439. Epub 2023 May 21. J Chemother. 2023. PMID: 37211906
Gene therapy approaches for sickle cell anemia.
Ulas T, Dal MS. Ulas T, et al. Transfus Apher Sci. 2023 Apr;62(2):103677. doi: 10.1016/j.transci.2023.103677. Epub 2023 Feb 24. Transfus Apher Sci. 2023. PMID: 36858830 Review. No abstract available.
International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report.
Ozatli D, Giden AO, Erkurt MA, Korkmaz S, Basci S, Ulas T, Turgut B, Yigenoglu TN, Hacibekiroglu T, Basturk A, Dal MS, Namdaroglu S, Hindilerden F, Hacioglu SK, Cagliyan GA, Ilhan G, Kacmaz M, Uysal A, Merter M, Ekinci O, Dursun FE, Tekinalp A, Demircioglu S, Sincan G, Acik DY, Akdeniz A, Ucar MA, Yeral M, Ciftciler R, Teke HU, Umit EG, Karakus A, Bilen Y, Yokus O, Albayrak M, Demir C, Okan V, Serefhanoglu S, Kartı S, Ozkurt ZN, Eser B, Aydogdu I, Kuku I, Cagirgan S, Sonmez M, Ozet G, Altuntas F. Ozatli D, et al. Among authors: ulas t. Transfus Apher Sci. 2023 Apr;62(2):103662. doi: 10.1016/j.transci.2023.103662. Epub 2023 Feb 24. Transfus Apher Sci. 2023. PMID: 36842884 Review.
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
Dal MS, Ulu BU, Uzay A, Akay OM, Beşışık S, Yenerel MN, Çelik S, Kaynar L, Yücel OK, Deveci B, Sönmez M, Mehtap Ö, Beköz HS, Sunu C, Salim O, Ulaş T, Kartı S, Altuntaş F, Ferhanoğlu B, Tuğlular TF. Dal MS, et al. Among authors: ulas t. Ann Hematol. 2023 Jan;102(1):133-140. doi: 10.1007/s00277-022-05052-x. Epub 2022 Nov 19. Ann Hematol. 2023. PMID: 36401621 Free PMC article.
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Akpinar S, Dogu MH, Celik S, Ekinci O, Hindilerden IY, Dal MS, Davulcu EA, Tekinalp A, Hindilerden F, Ozcan BG, Hacibekiroglu T, Erkurt MA, Bagci M, Namdaroglu S, Korkmaz G, Bilgir O, Cagliyan GA, Ozturk HBA, Serin I, Tiryaki TO, Ozatli D, Korkmaz S, Ulas T, Eser B, Turgut B, Altuntas F. Akpinar S, et al. Among authors: ulas t. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):169-173. doi: 10.1016/j.clml.2021.09.010. Epub 2021 Sep 15. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34629286
Pralatrexate experience in PTCL: A multicenter retrospective study from Turkey.
Sinan Dal M, Merdin A, Erkurt MA, Ekinci Ö, Albayrak M, Kabukcu Hacıoglu S, Kaya A, Dogu MH, Hindilerden F, Sarici A, Merter M, Reis Aras M, Akgun Caglıyan G, Kizil Cakar M, Aydogdu I, Kuku I, Korkmaz S, Ulas T, Eser B, Altuntas F. Sinan Dal M, et al. Among authors: ulas t. J BUON. 2021 Jul-Aug;26(4):1536-1539. J BUON. 2021. PMID: 34565016 Free article.
Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
Uncu Ulu B, Dal MS, Yönal Hindilerden İ, Akay OM, Mehtap Ö, Büyükkurt N, Hindilerden F, Güneş AK, Yiğenoğlu TN, Başcı S, Kızıl Çakar M, Yanardağ Açık D, Korkmaz S, Ulaş T, Özet G, Ferhanoğlu B, Nalçacı M, Altuntaş F. Uncu Ulu B, et al. Among authors: ulas t. J Chemother. 2022 May;34(3):190-198. doi: 10.1080/1120009X.2021.1976912. Epub 2021 Sep 13. J Chemother. 2022. PMID: 34514960
Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey.
Kalpakci Y, Hacibekiroglu T, Darcin T, AkgunCagliyan G, Cakar MK, Hacioglu SK, Ekinci O, Korkmaz S, Albayrak M, Dal MS, Dogan A, Ulas T, Eser B, Altuntas F. Kalpakci Y, et al. Among authors: ulas t. Transfus Apher Sci. 2021 Oct;60(5):103244. doi: 10.1016/j.transci.2021.103244. Epub 2021 Aug 25. Transfus Apher Sci. 2021. PMID: 34462219
79 results